Equities Analysts Issue Forecasts for AVBP Q1 Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – B. Riley issued their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a note issued to investors on Wednesday, March 19th. B. Riley analyst K. Patel forecasts that the company will post earnings per share of ($0.70) for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. B. Riley also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.30) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.75) EPS and FY2029 earnings at $0.40 EPS.

A number of other analysts also recently issued reports on AVBP. Guggenheim assumed coverage on shares of ArriVent BioPharma in a report on Monday, March 10th. They issued a “buy” rating and a $45.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 target price on shares of ArriVent BioPharma in a report on Friday, March 7th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $39.00.

ArriVent BioPharma Stock Performance

AVBP stock opened at $20.21 on Monday. The company’s fifty day moving average price is $24.82 and its 200-day moving average price is $26.68. ArriVent BioPharma has a one year low of $14.35 and a one year high of $36.37. The company has a market capitalization of $687.46 million, a PE ratio of -7.86 and a beta of 1.00.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.18.

Hedge Funds Weigh In On ArriVent BioPharma

Several institutional investors have recently bought and sold shares of AVBP. Suvretta Capital Management LLC increased its holdings in shares of ArriVent BioPharma by 21.7% in the 4th quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company’s stock worth $59,833,000 after buying an additional 400,838 shares during the last quarter. FMR LLC increased its stake in ArriVent BioPharma by 8.7% during the third quarter. FMR LLC now owns 2,119,695 shares of the company’s stock worth $49,813,000 after acquiring an additional 169,514 shares during the last quarter. Octagon Capital Advisors LP raised its position in ArriVent BioPharma by 4.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company’s stock valued at $54,862,000 after purchasing an additional 83,000 shares during the period. Infinitum Asset Management LLC purchased a new stake in ArriVent BioPharma during the fourth quarter valued at approximately $43,794,000. Finally, Novo Holdings A S lifted its stake in shares of ArriVent BioPharma by 1.0% in the 4th quarter. Novo Holdings A S now owns 1,520,627 shares of the company’s stock valued at $40,510,000 after purchasing an additional 15,312 shares during the last quarter. Institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.